Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $2.9 million.

  • Heron Therapeutics' Share-based Compensation rose 4.78% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 30.26%. This contributed to the annual value of $13.0 million for FY2024, which is 60.55% down from last year.
  • Heron Therapeutics' Share-based Compensation amounted to $2.9 million in Q3 2025, which was up 1.97% from $2.8 million recorded in Q2 2025.
  • Heron Therapeutics' Share-based Compensation's 5-year high stood at $13.9 million during Q2 2023, with a 5-year trough of $2.3 million in Q4 2024.
  • Over the past 3 years, Heron Therapeutics' median Share-based Compensation value was $3.4 million (recorded in 2024), while the average stood at $4.9 million.
  • As far as peak fluctuations go, Heron Therapeutics' Share-based Compensation skyrocketed by 34.26% in 2023, and later plummeted by 67.12% in 2024.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Share-based Compensation stood at $12.9 million in 2021, then declined by 18.42% to $10.5 million in 2022, then slumped by 58.87% to $4.3 million in 2023, then tumbled by 46.92% to $2.3 million in 2024, then rose by 4.78% to $2.9 million in 2025.
  • Its Share-based Compensation stands at $2.9 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.5 million for Q1 2025.